Loading...
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
BACKGROUND: To understand the extent to which a large-scale healthcare claims database (DB) captures the safety profile of eribulin mesylate (Halaven(®), Eisai Co., Ltd., Japan), we compared patient characteristics, drug use, and adverse events (AEs) between data for patients treated with eribulin r...
Na minha lista:
| Udgivet i: | Drugs Real World Outcomes |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6423272/ https://ncbi.nlm.nih.gov/pubmed/30847841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40801-019-0150-8 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|